Navigation Links
ADVENTRX Pharmaceuticals Announces Closing of Financing
Date:5/6/2010

SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has completed the previously announced sale of shares of its Series F convertible preferred stock pursuant to a registered direct offering to institutional investors, representing gross proceeds to ADVENTRX of approximately $19.2 million.  ADVENTRX plans to use the net proceeds from the offering to fund activities relating to acquiring and developing additional product candidates, to continue development of its current lead product candidates, and for general corporate purposes.

The convertible preferred stock is convertible into shares of ADVENTRX's common stock at the option of the investors at a conversion price of $3.7025 per share and will accrue a 2.19446320054018% cumulative dividend until May 6, 2020.  If the convertible preferred stock is converted at any time prior to May 6, 2020, ADVENTRX will pay the holder an amount equal to the total dividend that would accrue on the convertible preferred stock from the conversion date through May 6, 2020, or approximately $219.45 per $1,000 stated value of convertible preferred stock converted, less any dividend payments made with respect to the converted convertible preferred stock.  Approximately $4.2 million of the gross proceeds will be placed in an escrow account, which amounts will be released to make the dividend and other payments described above.

The investors also will receive series A warrants to
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... de octubre de 2014  PneumRx, Inc. ( ... la pulmonología intervencional, anunció hoy la conclusión de ... meses antes de lo programado. El Estudio Clínico RENEW ... de investigación (IDE) aprobada por la FDA (Administración ... espiral de reducción de volumen pulmonar PneumRx RePneu, ...
(Date:10/20/2014)... , Oct. 20, 2014  ResMed (NYSE: ... the ResMed Data Exchange program, a comprehensive suite ... equipment (HME) and other health care providers. ... access to critical patient information. It integrates valuable ... and U-Sleep™ patient management platforms with customers, in-house ...
(Date:10/20/2014)... 20, 2014  AnaptysBio, Inc., a leader in ... announced the appointment of Marco Londei , ... lead the preclinical and clinical development of AnaptysBio,s ... pleased to welcome Dr. Londei to AnaptysBio,s executive ... and Chief Executive Officer of AnaptysBio. "Dr. Londei,s ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3ResMed Launches ResMed Data Exchange 2AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
... REYKJAVIK, Iceland, July 1 The ... several new common,single-letter variants in the sequence of the human ... a multinational consortium of scientists,led by a team from deCODE ... 50,000 patients and control participants from fourteen countries.,It is published ...
... announces that it has reached the halfway mark (1,600 patients) ... G auging R esponsiveness with A V erifyNow(R) ... nd S afety). The trial is specifically designed ... for patients who are poor responders to clopidogrel (Plavix(R)). ...
Cached Medicine Technology:deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 2deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 3deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 4deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 5Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled 2
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ovarian ... to think outside the bra. She doesn’t try to hide ... awareness about women’s other lady parts. , "We have won ... color pink and everybody knows what you’re talking about,” Jess-Huff ... has not been won when it comes to gynecologic cancers. ...
(Date:10/20/2014)... 2014 Principle Business Enterprises, a family ... manufacturing top-of-the-line absorbent products. The company has recently ... popular brand, Tranquility® Premium Protection absorbent products. The ... gave its packaging a new look, and is currently ... to the public. , The new website, developed with ...
(Date:10/20/2014)... Rockynol Retirement Community broke ... 14. The $11 million project will include the latest ... kitchen with full-service restaurant style dining. , “We are ... class Assisted Living apartments,” said Kara Hanzie, Rockynol Executive ... quality of care and this investment is proof of ...
(Date:10/20/2014)... National Teen Driver Safety Week is October 19-25, ... Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining the National ... drivers to talk to their teens and always set the ... are the leading cause of death for U.S. teens. In ... and 859 (42%) of those teen drivers were killed in ...
(Date:10/20/2014)... DALLAS (PRWEB) October 20, 2014 It’s hard ... for many orphans and vulnerable children around the world, it’s ... by some people, many children are forced to walk barefoot ... for their families or play with their friends. , ... partnering with Air1 Radio in October to encourage ...
Breaking Medicine News(10 mins):Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3
... Message Brokering, SOA integration, and Complex-Event Processing (CEP) ... Ariz., March 30 First Choice Professionals, LLC., ... (Nasdaq: TIBX ), to provide healthcare ... a unified solution. FCP,s renowned healthcare integration group ...
... Recognized for Efficient Energy Performance KENILWORTH, N.J., March ... has named Schering-Plough Corporation as a 2009 ENERGY ... management and reductions in greenhouse gas emissions. The ... ceremony in Washington, D.C., on March 31, 2009.In ...
... Equipment,s LC Sprint reusable nebulizer and TREK S portable compressor ... of "ER" that will air Thursday at 9pm on NBC. ... of "ER," including George Clooney and Julianna Margulies, so the ... PARI nebulizers have been used on the show to highlight ...
... 30 Genaera Corporation (Nasdaq: GENR ) ... conserve existing cash resources in order to maintain the ... the first-in-class, highly selective inhibitor of PTP1B and Genaera,s ... diabetes and obesity, and explore strategic alternatives. The ...
... 30 Folding carton specialist Benson,Group, UK packaging company ... into the pharmaceutical labels sector with the purchase of ... and inspection,machine for its pharmaceutical-focused Medica Packaging business in ... customer demand as being the key driving factor behind,the ...
... MONDAY, March 30 (HealthDay News) -- Babies who gain weight ... more prone to obesity as toddlers, Harvard researchers report. , ... much younger," said study author Dr. Elsie M. Taveras. "Even ... start guiding parents about how to prevent rapid weight gain ...
Cached Medicine News:Health News:First Choice Professionals and TIBCO Announce Strategic Partnership to Advance Healthcare Integration 2Health News:EPA Names Schering-Plough 2009 EPA ENERGY STAR(R) Partner of the Year 2Health News:EPA Names Schering-Plough 2009 EPA ENERGY STAR(R) Partner of the Year 3Health News:PARI's LC Sprint & TREK S Featured in 'ER' Final Episode on NBC Thursday 2Health News:Genaera Corporation Implements Cash Conservation Plan 2Health News:Benson Group Moves into Pharma Labels Sector 2Health News:Benson Group Moves into Pharma Labels Sector 3Health News:Rapid Infant Weight Gain Linked to Childhood Obesity 2
The design and concept of the Alpina knee allows the choice of implanting a PCL retaining or a posterior stabilized prosthesis intraoperatively....
... tricompartmental total knee prosthesis stems from many ... design and manufacturing technologies have been used ... as well as a favorable pressure distribution ... keep wear to a minimum. The inherent ...
... StelKast's Proven Knee System is a long ... proven design. Available in both posterior stabilized ... Proven Knee System provides the flexibility needed ... standardization and ease of identification keeps the ...
... The FluoroNav Virtual ... Surgical Navigation Technologies has ... with exciting technology features ... images and three-dimensional models ...
Medicine Products: